Email ID
Password
Scrip   
Iressa gains a positive opinion for lung cancer in the EU
24 April 2009
John Davis

The EU's CHMP has recommended AstraZeneca's targeted oral therapy, gefitinib (Iressa), 250mg tablets, for use as first-line therapy in a subgroup of advanced lung cancer patients with a certain gene mutation.
Gefitinib is recommended by the CHMP for adults with locally advanced or metastatic...



Please Login to read the full article.
EVENTS
11 March 2010
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36